Yes. Generic apixaban has been available in the United States since late 2019, after the key composition-of-matter patent expired and exclusivity periods ended. The FDA approved multiple manufacturers to market AB-rated versions, which lets pharmacists substitute generic apixaban for brand Eliquis wherever state rules permit.
Below, you will find which manufacturers make it, why some pharmacies still dispense brand Eliquis, how the safety profile compares to the brand, and practical ways to lower your out-of-pocket cost starting today.
Apixaban and Eliquis Share the Same Active Ingredient
Apixaban is the generic name for the brand anticoagulant sold as Eliquis, originally approved by the FDA in 2012 for two main uses: lowering stroke risk in nonvalvular atrial fibrillation and treating or preventing deep vein thrombosis (DVT) and pulmonary embolism (PE). Bristol-Myers Squibb and Pfizer co-developed the drug, which is why both company names appear on the brand packaging.
Because apixaban is the active molecule in Eliquis, any generic version must match it at the molecular level. A true generic cannot legally launch until the manufacturer demonstrates FDA bioequivalence for the same 2.5 mg and 5 mg oral tablet strengths. That requirement protects you: an AB-rated generic is held to the same rate and extent of absorption as the brand in healthy volunteers, which is the FDA’s standard for therapeutic equivalence.
FDA-Approved Generics of Apixaban Already Exist
The FDA began approving generic apixaban in late 2019 after the key composition-of-matter patent and exclusivity periods lapsed. Once those protections cleared, multiple Abbreviated New Drug Application (ANDA) holders crossed the finish line. Manufacturers with FDA approval for generic apixaban in the U.S. include Mylan (now Viatris), Teva, Apotex, and Sandoz, among others.
What an AB Rating Actually Means for You
An AB rating from the FDA Orange Book signals therapeutic equivalence: the generic delivers the same amount of active ingredient into the bloodstream over the same time window as the brand. Pharmacists may substitute generic apixaban for Eliquis wherever state generic-substitution rules permit, and most approved versions carry this rating. That designation allows a one-for-one swap at the pharmacy counter without a new prescription.
How to Verify Current Approval Status
You can confirm current approvals by checking the FDA Orange Book directly, or by asking your pharmacist to run a real-time check on the day of dispensing. Pharmacy software pulls from the same authoritative source, so the answer at the register is current. If your prescription was written for “apixaban” rather than “Eliquis,” the substitution pathway is even smoother because the prescriber already signaled intent to use the generic name.
Why Some Pharmacies Still Seem to Stock Only Eliquis
Even with FDA approval in place, supply depends on whether a wholesaler has ordered the generic and whether your insurer has moved apixaban to a preferred formulary tier. Pharmacy shelves reflect what was ordered, not what exists in the market, so a stocked bottle of brand Eliquis does not mean a generic is unavailable. It means that particular store’s buyer chose brand inventory, often because of contract terms.
Formulary Placement and Pharmacy Benefit Manager Decisions
Some large pharmacy benefit managers continue to favor the brand on formulary during transition periods, which can make generic apixaban appear invisible at the counter even when it is technically on the market. If your plan lists brand Eliquis as the preferred product and apixaban generic as non-preferred, you may pay a higher copay for the generic than the brand, an oddity that frustrates patients and pharmacists alike.
Coverage changes typically lag behind approvals by several months as P&T committees review new entrants.
Manufacturer Contracts That Delay Broad Stocking
Rebate negotiations that stay unsettled for months after first approval often leave pharmacy chains with empty shelves for certain generics. Independent pharmacies often have more flexibility to order from whichever wholesaler stocks the lowest-priced version.
So if generics are already approved, why does the shelf often show only Eliquis?
If your pharmacy does not have generic apixaban on the shelf, the prescription can usually be transferred to one that does, or the pharmacist can special-order it within a day or two. Both options are routine.
Brand Versus Generic Apixaban on Safety and Effectiveness
AB-rated generic apixaban must demonstrate the same rate and extent of absorption as Eliquis in healthy volunteers, a standard the FDA treats as clinical equivalence. That is a high regulatory bar: the generic must fall within 80 to 125 percent of the brand’s bioavailability in controlled studies, with confidence intervals that confirm no clinically meaningful difference.
Why Anticoagulants Get Extra Scrutiny
For narrow-therapeutic-index drugs, the FDA requires tighter bioequivalence ranges. Apixaban is not classified in that higher-risk category. Its dosing is forgiving enough that standard AB-rated bioequivalence data is considered sufficient to support substitution, a position backed by postmarket pharmacovigilance.
Real-World Switching Data
Observational studies covering thousands of anticoagulant switches have found no rise in bleeding or clotting events between AB-rated brands and their generic counterparts. Pharmacovigilance signals after the late-2019 launch showed no spike in adverse event reports tied to the switch. You should still confirm any change with your prescriber and pharmacist, especially if you take other drugs that interact with apixaban, because concomitant medications can shift exposure independently of the brand-versus-generic question.
What Generic Apixaban Actually Costs Compared to Eliquis
Generic apixaban typically launches at a fraction of the brand list price, with early generic prices often falling by more than half for cash-paying customers. Brand Eliquis carries a monthly list price that often runs into the hundreds of dollars, making affordability a real barrier to long-term adherence for many patients. Once generics entered the market, the cash price at major U.S. chains dropped sharply, though your actual out-of-pocket depends heavily on insurance design.
| Coverage Scenario | Typical Monthly Cost (2024–2025) | Notes |
|---|---|---|
| Brand Eliquis, no insurance | $550–$700 | List price, varies by pharmacy |
| Generic apixaban, no insurance | $150–$350 | Discount programs can lower this further |
| Brand Eliquis, Medicare Part D | Tier 3 or 4 copay, often $40–$100+ | Until generic tier reassignment |
| Generic apixaban, Medicare Part D | Lower copay, frequently Tier 1 or 2 | Once plan year adopts generic tier |
| Commercial insurance, generic preferred | $0–$30 copay | Most common scenario after formulary update |
Insurance copays on generic apixaban are usually lower, and the drug frequently moves to a more favorable Medicare Part D tier once the plan year adopts the generic. Manufacturer copay cards, such as those historically offered through the Eliquis savings program, may no longer apply once a generic is dispensed, but other assistance options remain for those who qualify.
You should compare the cash price at discount pharmacies, your plan’s formulary tier, and any available foundation grants before paying full brand price.
Once effectiveness is off the table, the practical question becomes what you actually pay at the counter.
Practical Steps to Lower the Cost of Apixaban Right Now
You can take concrete action this week to reduce your monthly spend, regardless of whether your plan has caught up to the generic yet. The most common mistake is paying the brand copay at the pharmacy counter without asking whether a generic is actually available. Pharmacists often need a prompt to run the substitution check.
Steps That Actually Move the Needle
- Ask for the generic name: Confirm the prescription is written for “apixaban” rather than Eliquis so substitution can occur automatically at dispensing.
- Compare pharmacy prices: Cash prices for generic apixaban can vary by more than 50 percent between major retailers and verified discount programs, so a quick phone call pays off.
- Apply for Medicare Extra Help: If you are on Medicare and meet income limits, the Low-Income Subsidy program can drop your copay to a few dollars per fill.
- Check state assistance programs: Many states offer anticoagulant coverage for residents who fall into specific income brackets.
- Look into foundation grants: Independent nonprofits sometimes fund chronic-condition medications, including blood thinners, for eligible patients.
- Request a 90-day supply: Most plans offer lower per-day copays on extended fills, and it reduces how often you face the substitution question.
Skip unregulated overseas pharmacies or compounded apixaban, which are not FDA-approved substitutes and may carry real safety risks for an anticoagulant. The variability in unregulated products is exactly what bioequivalence testing exists to prevent.
When to Talk to Your Prescriber About Switching
Reach out to your prescriber if your insurance suddenly changes the formulary tier for apixaban, if you notice unexpected bruising or bleeding after a switch, or if you are starting a new interacting medication. Most switches are uneventful, but a brief check-in removes ambiguity. Pharmacists can also flag potential interactions you might not have considered, including over-the-counter NSAIDs and certain supplements that raise bleeding risk when paired with apixaban.
Bottom Line
Yes, generic apixaban is FDA-approved and has been since late 2019, carrying a therapeutic equivalence rating the agency treats as interchangeable with Eliquis. If you are still paying brand price, the gap is almost certainly formulary, stocking, or prescription language, not drug availability. Ask your prescriber to write the generic name, ask your pharmacist to run a substitution check, and compare cash prices across at least two or three pharmacies before paying full price.
FAQ
Is there a generic version of apixaban?
Yes. Multiple manufacturers received FDA approval starting in late 2019, and AB-rated generic apixaban is available in 2.5 mg and 5 mg tablet strengths across the United States. Your pharmacist can confirm which approved versions are currently in stock at your location.
Is generic apixaban available in the United States?
Yes. Generic apixaban has been on the U.S. market since late 2019, following FDA approval of multiple AB-rated manufacturers after the composition-of-matter patent expired.
When did generic apixaban become available in the U.S.?
FDA approval for generic apixaban began in late 2019, shortly after the key composition-of-matter patent and exclusivity periods expired. Broader market availability expanded over the following months as additional manufacturers received approval and pharmacy benefit managers updated their formularies.
Why is there no generic version of Eliquis yet?
There is. Generic apixaban has been FDA-approved since late 2019, and Eliquis is simply the brand name for the same active molecule. If you are still receiving brand Eliquis, the cause is usually prescription wording, pharmacy stocking, or formulary placement rather than drug availability.
How much cheaper is generic apixaban than brand Eliquis?
Cash-paying customers typically see generic apixaban priced at roughly half of brand Eliquis, sometimes lower with discount programs. Insured patients often pay a lower copay on the generic tier, and Medicare Part D plans usually move apixaban to a more favorable tier once the plan year adopts it.
Is generic apixaban as effective as brand-name Eliquis?
Yes. AB-rated generics must demonstrate the same rate and extent of absorption as the brand, which the FDA treats as clinical equivalence. Real-world data after the late-2019 launch showed no spike in bleeding or clotting events tied to the switch.
